A Study of the Effectiveness of Peginterferon Alfa-2a (Pegasys) and Ribavirin Treatment in Slovenian Hepatitis C (HCV) Patients

Roche

Status: Completed

Conditions: Hepatitis C, Chronic

Treatments: Drug: Peginterferon alfa-2a; Drug: Ribavirin

Study type: Observational

Funder types: Industry

Identifiers

NCT02556307

ML22263

Details and patient eligibility

About

In this Slovenian, multi-center, observational study, the effectiveness of standard of care Peginterferon alfa-2a + ribavirin treatment in adult patients with chronic hepatitis C (CHC) is examined. Patients were treated for 24- or 48-weeks, as prescribed by the treating physician, followed by a 24-week follow-up period.

Enrollment: 270 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male and female patients >/= 18 years
• Positive test for HCV
• Effective contraception as specified by the Peginterferon alfa-2a and/or ribavirin labels

Exclusion criteria

• Concomitant infection with HIV or hepatitis B
• Participation in a clinical trial within 30 days prior to study start
• Any contraindications specified in the Peginterferon alfa-2a and ribavirin product labels

Trial design

270 participants in 1 patient group

Peginterferon alfa-2a + Ribavirin

Treatment:

Drug: Ribavirin

Drug: Peginterferon alfa-2a